Laboratorio di biologia molecolare dell’istituto di ematologia e oncologia molecolare
Laboratorio di biologia molecolare dell’istituto di ematologia e oncologia molecolare is recorded as a service provider in 1 clinical trial. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 1 of 1 trials · Latest update first
A phase II, single-arm study of de-escalation and treatment-free remission in patients with chronic myeloid leukemia treated with nilotinib in first-line therapy followed by a second attempt after nilotinib and asciminib combination: DANTE study
Sponsor Novartis Farma S.p.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available3 trial-level findings · Read insights
- The study was conducted only in Italy, where all 135 participants were enrolled.
- Slow enrollment and an all-centre feasibility questionnaire identified a relevant gap in reaching the target; the planned sample size was reduced from 136 to 103 and statistical power from 90% to 80%.
- An amendment redefined sustained DMR, loosened a laboratory eligibility criterion, and reduced consolidation-period monitoring-visit frequency.
These findings describe the trial, not the service provider’s performance or responsibility.
Questions about this trial experience
What services are recorded for Laboratorio di biologia molecolare dell’istituto di ematologia e oncologia molecolare?
The 2026-10-09 snapshot links Laboratorio di biologia molecolare dell’istituto di ematologia e oncologia molecolare to 1 distinct CTIS trials. Recorded services include Analysis of BCR-ABL levels by ddPCR. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Laboratorio di biologia molecolare dell’istituto di ematologia e oncologia molecolare?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Laboratorio di biologia molecolare dell’istituto di ematologia e oncologia molecolare conducted?
The linked trials record locations in 1 country, including Italy. These are trial locations, not confirmed office locations or countries where Laboratorio di biologia molecolare dell’istituto di ematologia e oncologia molecolare delivered services.
What can this page tell me about Laboratorio di biologia molecolare dell’istituto di ematologia e oncologia molecolare's trial experience?
Browse 1 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Laboratorio di biologia molecolare dell’istituto di ematologia e oncologia molecolare. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Laboratorio di biologia molecolare dell’istituto di ematologia e oncologia molecolare